Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia — DEFINE-CABP

Community Acquired Bacterial Pneumonia Clinical Trial

Official title:
A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.

Clinical Trial Description

The purpose of this study is to determine if delafloxacin, an investigational drug, is safe and effective in the treatment of community-acquired bacterial pneumonia compared with moxifloxacin, or linezolid in the case of confirmed MRSA. ;

Study Design

Related Conditions & MeSH terms

Community Acquired Bacterial Pneumonia
Pneumonia
Pneumonia, Bacterial

Clinical Trial Details

NCT number	NCT02679573
Study type	Interventional
Source	Melinta Therapeutics, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	December 14, 2016
Completion date	August 7, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00202826` - Study of Fluid Collection of the Chest in Children With Pneumonia	Phase 3
Completed	`NCT01605864` - Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia	Phase 3
Withdrawn	`NCT01602874` - Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia	Phase 3
Withdrawn	`NCT00914888` - Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia	Phase 3